Aurinia Pharmaceuticals Inc
AUPHAurinia Pharmaceuticals Inc. is a global biotechnology company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. The company's flagship product, Lupkynis, is approved for the treatment of lupus nephritis, a serious complication of systemic lupus erythematosus. Aurinia specializes in innovative treatments targeting immune system pathways to address unmet medical needs.
Company News
The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.
The American College of Rheumatology has updated its guidelines for treating lupus nephritis, recommending early use of triple therapy (mycophenolate mofetil, glucocorticoids, and either Benlysta or a calcineurin inhibitor). However, current practice often delays initiating triple therapy until initial treatment failure.
The American Kidney Fund's Disaster Relief Program is providing emergency financial assistance to dialysis and recent transplant patients in areas affected by Hurricane Helene. The program has received generous support from various companies and individual donors to help cover expenses related to lost medications, housing, transportation, and per...
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
